CHF583.60
0.62%
SIX Swiss Exchange, Feb 21, 05:31 pm CET
ISIN
CH0013841017
Symbol
LONN
Sector
Industry

Lonza Stock price

CHF583.60
+13.40 2.35% 1M
+26.80 4.81% 6M
+47.80 8.92% YTD
+129.80 28.60% 1Y
-8.40 1.42% 3Y
+164.00 39.08% 5Y
+478.19 453.64% 10Y
SIX Swiss Exchange, Closing price Fri, Feb 21 2025
-0.60 0.10%
ISIN
CH0013841017
Symbol
LONN
Sector
Industry

Key metrics

Market capitalization CHF41.04b
Enterprise Value CHF44.10b
P/E (TTM) P/E ratio 65.35
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.71
P/S ratio (TTM) P/S ratio 6.24
P/B ratio (TTM) P/B ratio 4.30
Dividend yield 0.69%
Last dividend (FY24) CHF4.00
Revenue growth (TTM) Revenue growth -2.13%
Revenue (TTM) Revenue CHF6.57b
EBIT (operating result TTM) EBIT CHF843.00m
Free Cash Flow (TTM) Free Cash Flow CHF-108.00m
EPS (TTM) EPS CHF8.93
P/E forward 39.71
P/S forward 5.35
EV/Sales forward 5.74
Show more

Create a Free Account to create an Lonza alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Lonza Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Lonza forecast:

22x Buy
81%
5x Hold
19%

Analyst Opinions

27 Analysts have issued a Lonza forecast:

Buy
81%
Hold
19%

Financial data from Lonza

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
6,574 6,574
2% 2%
100%
- Direct Costs 4,549 4,549
5% 5%
69%
2,025 2,025
4% 4%
31%
- Selling and Administrative Expenses 535 535
3,721% 3,721%
8%
- Research and Development Expense - -
-
-
1,490 1,490
23% 23%
23%
- Depreciation and Amortization 647 647
4% 4%
10%
EBIT (Operating Income) EBIT 843 843
36% 36%
13%
Net Profit 636 636
3% 3%
10%

In millions CHF.

Don't miss a Thing! We will send you all news about Lonza directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lonza Stock News

marktEINBLICKE
22 days ago
Das Healthcare-Unternehmen Lonza blickt positiv in die Zukunft. Die Aktie ist aus Sicht der Point & Figure Charttechnik kaufenswert.
EQS
25 days ago
An ihrem Investor Update im Dezember 2024 kündigte Lonza die neue Vision und One-Lonza-Strategie an, die sich auf die Lonza Engine konzentriert, welche die einzigartigen Kern-kompetenzen des Unternehmens vereint, die eine herausragende Wertschöpfung ermöglichen. Als Teil dieser Strategie hat Lonz...
More Lonza News

Company Profile

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Pharma & Biotech; Specialty Ingredients; and Corporate. The Pharma & Biotech segment comprises development and manufacture of customized active pharmaceutical ingredients and biopharmaceuticals as well as formulation services and delivery systems. The Specialty Ingredients segment consists of two divisions, consumer health and consumer resources and protection. The Corporate segment includes corporate functions, such as finance and accounting, legal, communication, information technology, and human resources. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Wolfgang Wienand
Employees 18,686
Founded 1897
Website www.lonza.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today